Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Nutritional concerns in pediatric inflammatory bowel disease

  • Kim, Yong Joo (Department of Pediatrics, Hanyang University College of Medicine)
  • Received : 2015.10.14
  • Accepted : 2015.12.16
  • Published : 2016.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

The pathophysiology and fundamental etiologic mechanism of inflammatory bowel disease (IBD) is not well understood even though therapeutic regimens and drugs are rapidly evolutionary. IBD has complicated connections with genetic, immunologic, gut microbial, environmental, and nutritional factors. It is not clearly well known to the physicians how to feed, what nutrients are more helpful, and what food to be avoided. This review discusses the issues of growth and important nutritional concerns in the management of IBD in childhood.

Keywords

References

  1. Vortia E, Kay M, Wyllie R. The role of growth hormone and insulin- like growth factor-1 in Crohn's disease: implications for therapeutic use of human growth hormone in pediatric patients. Curr Opin Pediatr 2011;23:545-51. https://doi.org/10.1097/MOP.0b013e32834a7810
  2. Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions. Inflamm Bowel Dis 2007;13:620-8. https://doi.org/10.1002/ibd.20115
  3. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25. https://doi.org/10.1006/cyto.1995.1003
  4. Ladner KJ, Caligiuri MA, Guttridge DC. Tumor necrosis factorregulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem 2003;278:2294-303. https://doi.org/10.1074/jbc.M207129200
  5. Martensson K, Chrysis D, Savendahl L. Interleukin-1beta and TNFalpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004;19:1805-12. https://doi.org/10.1359/JBMR.040805
  6. Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S, et al. The effects of anti-TNF-${\alpha}$ treatment with adalimumab on growth in children with Crohn's disease (CD). J Crohns Colitis 2012;6:337-44. https://doi.org/10.1016/j.crohns.2011.09.004
  7. Gavin J, Anderson CE, Bremner AR, Beattie RM. Energy intakes of children with Crohn's disease treated with enteral nutrition as primary therapy. J Hum Nutr Diet 2005;18:337-42. https://doi.org/10.1111/j.1365-277X.2005.00631.x
  8. Seidman E, LeLeiko N, Ament M, Berman W, Caplan D, Evans J, et al. Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991;12:424-38. https://doi.org/10.1097/00005176-199105000-00004
  9. Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGFbinding proteins in children and adults. J Clin Endocrinol Metab 1995;80:443-9.
  10. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106. https://doi.org/10.1079/PNS200070
  11. Wine E, Reif SS, Leshinsky-Silver E, Weiss B, Shaoul RR, Shamir R, et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 2004;114:1281-6. https://doi.org/10.1542/peds.2004-0417
  12. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
  13. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993;105:681-91. https://doi.org/10.1016/0016-5085(93)90883-E
  14. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 1993;34:939-43. https://doi.org/10.1136/gut.34.7.939
  15. Mallon DP, Suskind DL. Nutrition in pediatric inflammatory bowel disease. Nutr Clin Pract 2010;25:335-9. https://doi.org/10.1177/0884533610373773
  16. Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008;52:867-74. https://doi.org/10.1002/mnfr.200700156
  17. Santucci NR, Alkhouri RH, Baker RD, Baker SS. Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;59:455-7. https://doi.org/10.1097/MPG.0000000000000477
  18. Nowak JK, Grzybowska-Chlebowczyk U, Landowski P, Szaflarska- Poplawska A, Klincewicz B, Adamczak D, et al. Prevalence and correlates of vitamin K deficiency in children with inflammatory bowel disease. Sci Rep 2014;4:4768.
  19. Grunbaum A, Holcroft C, Heilpern D, Gladman S, Burstein B, Menard M, et al. Dynamics of vitamin D in patients with mild or inactive inflammatory bowel disease and their families. Nutr J 2013;12:145. https://doi.org/10.1186/1475-2891-12-145
  20. Gerasimidis K, Edwards C, Stefanowicz F, Galloway P, McGrogan P, Duncan A, et al. Micronutrient status in children with IBD: true deficiencies or epiphenomenon of the systemic inflammatory response. J Pediatr Gastroenterol Nutr 2013;56:e50-1.
  21. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60. https://doi.org/10.1056/NEJM199606133342401
  22. De Ley M, de Vos R, Hommes DW, Stokkers P. Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(4):CD005986.
  23. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012;487:104-8. https://doi.org/10.1038/nature11225
  24. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012;4:1095-119. https://doi.org/10.3390/nu4081095
  25. Okada Y, Tsuzuki Y, Sato H, Narimatsu K, Hokari R, Kurihara C, et al. Trans fatty acids exacerbate dextran sodium sulphateinduced colitis by promoting the up-regulation of macrophagederived proinflammatory cytokines involved in T helper 17 cell polarization. Clin Exp Immunol 2013;174:459-71. https://doi.org/10.1111/cei.12200
  26. Monk JM, Hou TY, Turk HF, Weeks B, Wu C, McMurray DN, et al. Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesityassociated Th17 cell-mediated inflammation during colitis. PLoS One 2012;7:e49739. https://doi.org/10.1371/journal.pone.0049739
  27. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999;19:91-122. https://doi.org/10.1146/annurev.nutr.19.1.91
  28. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5. https://doi.org/10.1002/art.1780290703
  29. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32. https://doi.org/10.1016/S0016-5085(97)70215-4
  30. Yakut M, Ustun Y, Kabacam G, Soykan I. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med 2010;21:320-3. https://doi.org/10.1016/j.ejim.2010.05.007
  31. Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood 2008;112:2214-21. https://doi.org/10.1182/blood-2008-03-040253
  32. Paller AS. Cutaneous changes associated with inflammatory bowel disease. Pediatr Dermatol 1986;3:439-45. https://doi.org/10.1111/j.1525-1470.1986.tb00647.x
  33. Harries AD, Brown R, Heatley RV, Williams LA, Woodhead S, Rhodes J. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut 1985;26:1197-203. https://doi.org/10.1136/gut.26.11.1197
  34. Schoon EJ, Müller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001;48:473-7. https://doi.org/10.1136/gut.48.4.473
  35. Solomons NW, Rosenberg IH, Sandstead HH, Vo-Khactu KP. Zinc deficiency in Crohn's disease. Digestion 1977;16:87-95. https://doi.org/10.1159/000198059
  36. Schoelmerich J, Becher MS, Hoppe-Seyler P, Matern S, Haeussinger D, Loehle E, et al. Zinc and vitamin A deficiency in patients with Crohn's disease is correlated with activity but not with localization or extent of the disease. Hepatogastroenterology 1985;32:34-8.
  37. Basson A. Vitamin D and Crohn's disease in the adult patient: a review. JPEN J Parenter Enteral Nutr 2014;38:438-58. https://doi.org/10.1177/0148607113506013
  38. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005;40:1058-65. https://doi.org/10.1080/00365520510023198
  39. Werner T, Wagner SJ, Martínez I, Walter J, Chang JS, Clavel T, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 2011;60:325-33. https://doi.org/10.1136/gut.2010.216929
  40. Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol 2008;19:229-34. https://doi.org/10.1097/MOL.0b013e3282fee935
  41. Tilg H, Kaser A. Diet and relapsing ulcerative colitis: take off the meat? Gut 2004;53:1399-401. https://doi.org/10.1136/gut.2003.035287
  42. Bjerrum JT, Nielsen OH, Hao F, Tang H, Nicholson JK, Wang Y, et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res 2010;9:954-62. https://doi.org/10.1021/pr9008223

Cited by

  1. Dietary Management of Pediatric Inflammatory Bowel Disease vol.22, pp.11, 2016, https://doi.org/10.1089/jmf.2019.0063